Royal Bank Of Canada Reneo Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.51 - $1.9 $1,109 - $1,396	-735 Reduced 98.79%	9 $0
Q1 2024 Nov 05, 2024	BUY	$1.59 - $1.74 $1,168 - $1,278	735 Added 8166.67%	744 $1,000
Q1 2024 May 15, 2024	SELL	$1.59 - $1.74 $3,218 - $3,521	-2,024 Reduced 73.12%	744 $1,000
Q4 2023 Feb 14, 2024	BUY	$1.34 - $8.43 $1,062 - $6,684	793 Added 40.15%	2,768 $4,000
Q3 2023 Nov 14, 2023	BUY	$5.44 - $8.13 $5,565 - $8,316	1,023 Added 107.46%	1,975 $15,000
Q2 2023 Aug 14, 2023	BUY	$5.44 - $10.5 $5,178 - $9,996	952 New	952 $6,000
Q3 2022 Nov 14, 2022	BUY	$2.35 - $4.85 $141 - $291	60 Added 400.0%	75 $0
Q2 2022 Aug 15, 2022	SELL	$1.96 - $3.04 $1,015 - $1,574	-518 Reduced 97.19%	15 $0
Q1 2022 May 16, 2022	SELL	$2.94 - $9.07 $4,651 - $14,348	-1,582 Reduced 74.8%	533 $2,000
Q4 2021 Feb 14, 2022	BUY	$6.07 - $9.68 $8,145 - $12,990	1,342 Added 173.61%	2,115 $18,000
Q3 2021 Nov 15, 2021	BUY	$6.28 - $11.07 $2,147 - $3,785	342 Added 79.35%	773 $6,000
Q2 2021 Aug 16, 2021	BUY	$7.78 - $15.0 $3,353 - $6,465	431 New	431 $4,000

31M

50.8K

Ticker RPHM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,479,600
Market Cap $41.1M
Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.